Starting in 2015, psychiatrists will have to juggle antidepressant selections for Medicare patients. What might this mean for your patients?
Insurers appear to have plenty of leeway to continue—or even expand—the kind of anti-psychiatrist policies at the core of 2 lawsuits filed last year. Details here.
Come next year, psychiatrists will start seeing patients who have purchased new individual and small-group health plans on the state exchanges mandated by the Affordable Care Act.
There is wide agreement that memory loss associated with ECT is short-term, usually temporary, and rarely has a major impact, “although it shouldn’t be taken lightly,” according to Ross.
All members of the mental health community opposed the use of standardized testing to determine deviations from the mean. But the consensus fell apart thereafter.
Electroconvulsive therapy (ECT) devices are undergoing FDA scrutiny and could become subject to new requirements and restrictions that affect their use by psychiatrists. The FDA is considering whether to keep ECT devices in their current Class III category or drop them to Class II.
Congress substituted a 0.5% increase in Medicare fees for the first 6 months of 2008 for the 10% reduction that would otherwise have been enacted. That reduction in what is called the Medicare fee "update" was predetermined by a formula Congress itself put in place.